Literature DB >> 14993492

Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats.

Yung-Ming Chen1, Yee-Yung Ng, Shuei-Liong Lin, Wen-Chih Chiang, Hui Y Lan, Tun-Jun Tsai.   

Abstract

BACKGROUND: Crescentic glomerulonephritis is a rapidly progressive form of glomerulonephritis, but treatment remains non-specific. The methylxanthine derivative pentoxifylline (PTX) is a clinically available phosphodiesterase inhibitor with anti-inflammatory and immunoregulatory activities. This study examined whether PTX has beneficial effects in a rat model of anti-glomerular basement membrane (GBM) crescentic glomerulonephritis.
METHODS: Experimental crescentic glomerulonephritis was induced in Wistar rats by intravenous injection of rabbit anti-rat GBM serum and treated with either vehicle (phosphate-buffered saline) or PTX (0.1 g/kg/day) intravenously on a daily basis. Groups of six animals were euthanized at days 3, 7, 14 or 28 after induction of disease. Effects of PTX on renal function, histology and expression of cytokines, chemokines and adhesion molecules were determined.
RESULTS: Compared with the vehicle-treated nephritic rats, PTX treatment beginning at the start of the nephritis significantly suppressed mRNA expression of tumour necrosis factor (TNF)-alpha, but not interleukin-1 beta, throughout the course of nephritis. Moreover, PTX decreased renal mRNAs for intercellular adhesion molecule-1 (ICAM-1), monocyte chemoattractant protein-1 (MCP-1), regulated on activation, normal T-cell expressed and secreted (RANTES) and osteopontin (OPN) at all time points examined. These effects were associated with a significant inhibition of macrophage and T-cell infiltration, a reduction of 24-h urinary protein excretion (50-75%, P<0.05), an improvement of histological damage including glomerular crescent formation (60-70%, P<0.01) and a decrease of cortical mRNAs for type I (alpha 1) collagen and fibronectin. The efficacy of PTX could also be seen, though to a lesser extent, in rats with established nephritis.
CONCLUSIONS: PTX is an effective anti-inflammatory and immunomodulatory agent capable of suppressing rat crescentic glomerulonephritis. Inhibition of renal TNF-alpha, ICAM-1, RANTES, MCP-1 and OPN expression may be a mechanism whereby PTX suppresses progressive renal injury in rat crescentic glomerulonephritis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14993492     DOI: 10.1093/ndt/gfh127

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  11 in total

Review 1.  Inflammation and diabetic nephropathy.

Authors:  Carmen Mora; Juan F Navarro
Journal:  Curr Diab Rep       Date:  2006-12       Impact factor: 4.810

Review 2.  Effect of pentoxifylline in proteinuric chronic kidney disease: a systematic review and meta-analysis.

Authors:  Xiangpin Jiang; Shengguo Zhou; Jing Yao; Xianglei Kong; Meiyu Cui
Journal:  J Nephrol       Date:  2015-10-28       Impact factor: 3.902

3.  The glomerulosclerosis of aging in females: contribution of the proinflammatory mesangial cell phenotype to macrophage infiltration.

Authors:  Feng Zheng; Qing-Li Cheng; Anna-Rita Plati; Shui Qin Ye; Mariana Berho; Anita Banerjee; Mylene Potier; Edgar A Jaimes; Hong Yu; You-Fei Guan; Chung-Ming Hao; Liliane J Striker; Gary E Striker
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

Review 4.  Methylxanthines and the kidney.

Authors:  Hartmut Osswald; Jürgen Schnermann
Journal:  Handb Exp Pharmacol       Date:  2011

5.  Prolonged administration enhances the renoprotective effect of pentoxifylline via anti-inflammatory activity in streptozotocin-induced diabetic nephropathy.

Authors:  Kum Hyun Han; Sang Youb Han; Han Seong Kim; Young Sun Kang; Dae Ryong Cha
Journal:  Inflammation       Date:  2010-06       Impact factor: 4.092

6.  Effects of pentoxifylline in adriamycin-induced renal disease in rats.

Authors:  Yusuf Usta; Ugur Burcin Ismailoglu; Aysin Bakkaloglu; Dicle Orhan; Nesrin Besbas; Inci Sahin-Erdemli; Seza Ozen
Journal:  Pediatr Nephrol       Date:  2004-06-16       Impact factor: 3.714

7.  Effect of pentoxifylline on microalbuminuria in diabetic patients: a randomized controlled trial.

Authors:  Shahrzad Shahidi; Marziyeh Hoseinbalam; Bijan Iraj; Mojtaba Akbari
Journal:  Int J Nephrol       Date:  2015-03-22

8.  Pentoxifylline Protects the Rat Liver Against Fibrosis and Apoptosis Induced by Acute Administration of 3,4-Methylenedioxymethamphetamine (MDMA or Ecstasy).

Authors:  Shabnam Movassaghi; Zahra Nadia Sharifi; Farzaneh Mohammadzadeh; Mansooreh Soleimani
Journal:  Iran J Basic Med Sci       Date:  2013-08       Impact factor: 2.699

Review 9.  Therapeutic efficacy of pentoxifylline on proteinuria and renal progression: an update.

Authors:  Yung-Ming Chen; Wen-Chih Chiang; Shuei-Liong Lin; Tun-Jun Tsai
Journal:  J Biomed Sci       Date:  2017-11-13       Impact factor: 8.410

Review 10.  Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients.

Authors:  Bruce M Hendry; Nina Stafford; Ahran D Arnold; Arvind Sangwaiya; Vijay Manglam; Stuart D Rosen; Jayantha Arnold
Journal:  Pharmacol Res Perspect       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.